Search

Displaying results 4661 - 4670 of 10000 in total
  1. Drug

    KAI-1455

    go.drugbank.com/drugs/DB06064
    Experimental

    In preclinical studies, KAI-1455 showed a dramatic reduction in infarct size when delivered prior to the ischemic insult. … Several studies have demonstrated that epsilon PKC plays a key role in cytoprotection during periods of ischemia.

  2. Drug

    Dihydrofolic Acid

    go.drugbank.com/drugs/DB02015
    Investigational

    Mixtures: EnLyte Extra-LN
  3. Drug

    Ubenimex

    go.drugbank.com/drugs/DB03424
    Investigational

    It is being studied for use in the treatment of acute myelocytic leukemia. … Ubenimex (also known as bestatin) is a competitive protease inhibitor. It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N.

  4. Drug

    Methyl salicylate 2-ethylbutyrate

    go.drugbank.com/drugs/DB14130
    Investigational

    Mixtures: Thera Derm Roll On
  5. Drug

    Allicin

    go.drugbank.com/drugs/DB11780
    Investigational

    Allicin has been used in trials studying the treatment of Follicular Lymphoma.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Silmitasertib

    go.drugbank.com/drugs/DB15408
    Investigational

    Silmitasertib is under investigation in clinical trial NCT03904862 (Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery).

    Categories: Casein Kinase II, antagonists & inhibitors
  7. Drug

    AEOL-10150

    go.drugbank.com/drugs/DB05874
    Experimental

    AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.

  8. Drug

    IPH 2101

    go.drugbank.com/drugs/DB06049
    Investigational

    IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.

  9. Drug

    SLx-4090

    go.drugbank.com/drugs/DB05678
    Investigational

    SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes. [A33218]

  10. Drug

    NM-702

    go.drugbank.com/drugs/DB05505
    Investigational

    Therapeutic options to improve exercise performance in these patients are limited … It is estimated that about 6 million people suffer from intermittent claudication in the USA, with only 10 percent of these people currently receiving treatment.